These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26056105)

  • 1. RMP exposure is lower in HIV-infected TB patients receiving intermittent than daily anti-tuberculosis treatment.
    Hemanth Kumar AK; Narendran G; Kumar RS; Ramachandran G; Sekar L; Raja K; Swaminathan S
    Int J Tuberc Lung Dis; 2015 Jul; 19(7):805-7. PubMed ID: 26056105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
    Ramachandran G; Kumar AK; Kannan T; Bhavani PK; Kumar SR; Gangadevi NP; Banurekha VV; Sudha V; Venkatesh S; Ravichandran N; Kalpana S; Mathevan G; Sanjeeva GN; Agarwal D; Swaminathan S
    Pediatr Infect Dis J; 2016 May; 35(5):530-4. PubMed ID: 26825153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.
    Ramachandran G; Kumar AK; Bhavani PK; Kannan T; Kumar SR; Gangadevi NP; Banurekha VV; Sekar L; Ravichandran N; Mathevan G; Sanjeeva GN; Dayal R; Swaminathan S
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1162-7. PubMed ID: 25487804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial.
    Gopalan N; Santhanakrishnan RK; Palaniappan AN; Menon PA; Lakshman S; Chandrasekaran P; Sivaramakrishnan GN; Reddy D; Kannabiran BP; Agiboth HKK; Krishnamoorthy V; Rathinam S; Chockalingam C; Manoharan T; Ayyamperumal M; Jayanthi N; Satagopan K; Narayanan R; Krishnaraja R; Sathiyavelu S; Kesavamurthy B; Suresh C; Selvachitiram M; Arasan G; Susaimuthu S; Rathinam P; Angamuthu P; Jayabal L; Murali L; Ramachandran R; Tripathy SP; Swaminathan S
    JAMA Intern Med; 2018 Apr; 178(4):485-493. PubMed ID: 29507938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis.
    Perlman DC; Segal Y; Rosenkranz S; Rainey PM; Remmel RP; Salomon N; Hafner R; Peloquin CA;
    Clin Infect Dis; 2005 Dec; 41(11):1638-47. PubMed ID: 16267738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
    Swaminathan S; Narendran G; Venkatesan P; Iliayas S; Santhanakrishnan R; Menon PA; Padmapriyadarsini C; Ramachandran R; Chinnaiyan P; Suhadev M; Sakthivel R; Narayanan PR
    Am J Respir Crit Care Med; 2010 Apr; 181(7):743-51. PubMed ID: 19965813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifampicin pharmacokinetics in children under the Revised National Tuberculosis Control Programme, India, 2009.
    Arya A; Roy V; Lomash A; Kapoor S; Khanna A; Rangari G
    Int J Tuberc Lung Dis; 2015 Apr; 19(4):440-5. PubMed ID: 25860000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of standard dose regimens of rifampicin in patients with pulmonary tuberculosis in Pakistan.
    Shaheen A; Najmi MH; Saeed W; Farooqi ZU
    Scand J Infect Dis; 2012 Jun; 44(6):459-64. PubMed ID: 22224832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection.
    Chaisson RE; Clermont HC; Holt EA; Cantave M; Johnson MP; Atkinson J; Davis H; Boulos R; Quinn TC; Halsey NA
    Am J Respir Crit Care Med; 1996 Oct; 154(4 Pt 1):1034-8. PubMed ID: 8887603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.
    Hemanth Kumar AK; Kannan T; Chandrasekaran V; Sudha V; Vijayakumar A; Ramesh K; Lavanya J; Swaminathan S; Ramachandran G
    Int J Tuberc Lung Dis; 2016 Sep; 20(9):1236-41. PubMed ID: 27510252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.
    Saleri N; Dembélé SM; Villani P; Carvalho AC; Cusato M; Bonkoungou V; Nacanabo R; Kouanda S; Comelli M; Regazzi M; Matteelli A
    J Antimicrob Chemother; 2012 Feb; 67(2):469-72. PubMed ID: 22028201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of thrice weekly DOTS in tuberculosis patients with and without HIV co-infection: an observational study.
    Vashishtha R; Mohan K; Singh B; Devarapu SK; Sreenivas V; Ranjan S; Gupta D; Sinha S; Sharma SK
    BMC Infect Dis; 2013 Oct; 13():468. PubMed ID: 24099345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala.
    Okwera A; Johnson JL; Luzze H; Nsubuga P; Kayanja H; Cohn DL; Nunn P; Ellner JJ; Whalen CC; Mugerwa RD
    Int J Tuberc Lung Dis; 2006 Jan; 10(1):39-44. PubMed ID: 16466035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
    Ramachandran G; Hemanth Kumar AK; Bhavani PK; Poorana Gangadevi N; Sekar L; Vijayasekaran D; Banu Rekha VV; Ramesh Kumar S; Ravichandran N; Mathevan G; Swaminathan S
    Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance.
    Reves R; Heilig CM; Tapy JM; Bozeman L; Kyle RP; Hamilton CD; Bock N; Narita M; Wing D; Hershfield E; Goldberg SV;
    Int J Tuberc Lung Dis; 2014 May; 18(5):571-80. PubMed ID: 24903795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of rifampicin, isoniazid & pyrazinamide during daily & intermittent dosing: A preliminary study.
    Ramachandran G; Hemanth Kumar AK; Kannan T; Thangakunam B; Shankar D; Christopher DJ
    Indian J Med Res; 2023; 157(2&3):211-215. PubMed ID: 36861539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children.
    Donald PR; Maritz JS; Diacon AH
    Tuberculosis (Edinb); 2011 May; 91(3):196-207. PubMed ID: 21429802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.
    Swaminathan S; Deivanayagam CN; Rajasekaran S; Venkatesan P; Padmapriyadarsini C; Menon PA; Ponnuraja C; Dilip M
    Natl Med J India; 2008; 21(1):3-8. PubMed ID: 18472696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
    Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global guidelines for treatment of tuberculosis among persons living with HIV: unresolved issues.
    Kumar A; Kumar AM; Gupta D; Kanchar A; Mohammed S; Srinath S; Tripathy S; Rajasekaran S; Chan PL; Swaminathan S; Dewan PK
    Int J Tuberc Lung Dis; 2012 May; 16(5):573-8. PubMed ID: 22507931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.